Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1985 1
2000 2
2001 1
2004 1
2006 2
2007 3
2008 3
2010 1
2011 2
2012 1
2015 1
2016 1
2017 1
2018 1
2019 2
2020 2
2021 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for daily coulthard
Search for Daisy Coulthard instead (1 results)
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
Femminella GD, Frangou E, Love SB, Busza G, Holmes C, Ritchie C, Lawrence R, McFarlane B, Tadros G, Ridha BH, Bannister C, Walker Z, Archer H, Coulthard E, Underwood BR, Prasanna A, Koranteng P, Karim S, Junaid K, McGuinness B, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Harrison J, Hölscher C, Brooks DJ, Passmore AP, Ballard C, Edison P. Femminella GD, et al. Trials. 2019 Apr 3;20(1):191. doi: 10.1186/s13063-019-3259-x. Trials. 2019. PMID: 30944040 Free PMC article. Clinical Trial.
A total of 206 participants will be randomised to receive either liraglutide or placebo as a daily injection for a year. The primary outcome will be the change in cerebral glucose metabolic rate in the cortical regions (hippocampus, medial temporal lobe, and posterior cing …
A total of 206 participants will be randomised to receive either liraglutide or placebo as a daily injection for a year. The primary …
Mild cognitive impairment: the Manchester consensus.
Dunne RA, Aarsland D, O'Brien JT, Ballard C, Banerjee S, Fox NC, Isaacs JD, Underwood BR, Perry RJ, Chan D, Dening T, Thomas AJ, Schryer J, Jones AM, Evans AR, Alessi C, Coulthard EJ, Pickett J, Elton P, Jones RW, Mitchell S, Hooper N, Kalafatis C, Rasmussen JGC, Martin H, Schott JM, Burns A. Dunne RA, et al. Age Ageing. 2021 Jan 8;50(1):72-80. doi: 10.1093/ageing/afaa228. Age Ageing. 2021. PMID: 33197937 Free PMC article.
MCI is a heterogenous clinical syndrome reflecting a change in cognitive function and deficits on neuropsychological testing but relatively intact activities of daily living. MCI is a risk state for further cognitive and functional decline with 5-15% of people developing d …
MCI is a heterogenous clinical syndrome reflecting a change in cognitive function and deficits on neuropsychological testing but relatively …
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial.
Kehoe PG, Turner N, Howden B, Jarutyte L, Clegg SL, Malone IB, Barnes J, Nielsen C, Sudre CH, Wilson A, Thai NJ, Blair PS, Coulthard E, Lane JA, Passmore P, Taylor J, Mutsaerts HJ, Thomas DL, Fox NC, Wilkinson I, Ben-Shlomo Y; RADAR investigators. Kehoe PG, et al. Lancet Neurol. 2021 Nov;20(11):895-906. doi: 10.1016/S1474-4422(21)00263-5. Lancet Neurol. 2021. PMID: 34687634 Free PMC article. Clinical Trial.
After undergoing a 4-week, open-label phase of active treatment then washout, participants were randomly assigned (1:1) oral over-encapsulated preparations of either 100 mg losartan (after an initial two-dose titration stage) or matched placebo daily for 12 months. Randomi …
After undergoing a 4-week, open-label phase of active treatment then washout, participants were randomly assigned (1:1) oral over-encapsulat …
Imaging and diagnostic criteria for Multiple Sclerosis: are we there yet?
Josey L, Curley M, Jafari Mousavi F, Taylor BV, Lucas R, Coulthard A. Josey L, et al. J Med Imaging Radiat Oncol. 2012 Dec;56(6):588-93. doi: 10.1111/j.1754-9485.2012.02448.x. Epub 2012 Sep 12. J Med Imaging Radiat Oncol. 2012. PMID: 23210576 Review.
CONCLUSIONS: Radiologists must recognise that there are specific diagnostic criteria for MS that continue to evolve as a result of new research, improved technology and clinical experience and it is crucial that these criteria be applied in daily practice. It should be evi …
CONCLUSIONS: Radiologists must recognise that there are specific diagnostic criteria for MS that continue to evolve as a result of new resea …
Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
Coulthard KP, Peckham DG, Conway SP, Smith CA, Bell J, Turnidge J. Coulthard KP, et al. J Cyst Fibros. 2007 Apr;6(2):125-30. doi: 10.1016/j.jcf.2006.05.015. Epub 2006 Jul 7. J Cyst Fibros. 2007. PMID: 16829216 Free article.
BACKGROUND: : Once daily intravenous aminoglycoside dosing (ODD) is widely used to treat acute Pseudomonas aeruginosa exacerbations in patients with cystic fibrosis. ...The exposure of 5 children with reduced tobramycin clearances was simulated at the usual recommended dos …
BACKGROUND: : Once daily intravenous aminoglycoside dosing (ODD) is widely used to treat acute Pseudomonas aeruginosa exacerbations i …
Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study.
Master V, Roberts GW, Coulthard KP, Baghurst PA, Martin A, Roberts ME, Onishko CR, Martin AJ, Linke RJ, Holmes M, Jarvinen A, Kennedy D, Colebatch KA, Hansman D, Parsons DW. Master V, et al. Pediatr Pulmonol. 2001 May;31(5):367-76. doi: 10.1002/ppul.1060. Pediatr Pulmonol. 2001. PMID: 11340683 Clinical Trial.
CF patients with PA-induced pulmonary exacerbations were allocated to receive either once-daily tobramycin (Mono) or conventional therapy with tobramycin/ceftazidime given 8-hourly (Conv). ...Combination antibacterial therapy appears to offer no clinical advantage over onc …
CF patients with PA-induced pulmonary exacerbations were allocated to receive either once-daily tobramycin (Mono) or conventional the …
Quality assurance for MRI: practical experience.
Firbank MJ, Harrison RM, Williams ED, Coulthard A. Firbank MJ, et al. Br J Radiol. 2000 Apr;73(868):376-83. doi: 10.1259/bjr.73.868.10844863. Br J Radiol. 2000. PMID: 10844863
Signal-to-noise ratio (SNR) and image uniformity were measured daily from spin echo images acquired using a quadrature send-receive head coil and from a gradient echo sequence using the Helmholtz body coil. ...
Signal-to-noise ratio (SNR) and image uniformity were measured daily from spin echo images acquired using a quadrature send-receive h …
Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW. Bergen PJ, et al. J Antimicrob Chemother. 2008 Mar;61(3):636-42. doi: 10.1093/jac/dkm511. Epub 2008 Jan 28. J Antimicrob Chemother. 2008. PMID: 18227094
CONCLUSIONS: No difference in overall bacterial kill was observed when the recommended maximum daily dose was administered at 8, 12 or 24 h intervals. However, the 8 hourly regimen appeared most effective at minimizing emergence of resistance....
CONCLUSIONS: No difference in overall bacterial kill was observed when the recommended maximum daily dose was administered at 8, 12 o …
Losartan to slow the progression of mild-to-moderate Alzheimer’s disease through angiotensin targeting: the RADAR RCT.
Kehoe PG, Turner N, Howden B, Jarutyt L, Clegg SL, Malone IB, Barnes J, Nielsen C, Sudre CH, Wilson A, Thai NJ, Blair PS, Coulthard EJ, Lane JA, Passmore P, Taylor J, Mutsaerts HJ, Thomas DL, Fox NC, Wilkinson I, Ben-Shlomo Y. Kehoe PG, et al. Southampton (UK): NIHR Journals Library; 2021 Nov. Southampton (UK): NIHR Journals Library; 2021 Nov. PMID: 34748298 Free Books & Documents. Review.
INTERVENTION: The intervention was either 100 mg of overencapsulated losartan (Teva Pharmaceuticals Industries Ltd, Petah Tikva, Israel) daily or a matched placebo for 12 months. MAIN OUTCOME MEASURES: Difference in brain atrophy, represented by measurement of whole-brain …
INTERVENTION: The intervention was either 100 mg of overencapsulated losartan (Teva Pharmaceuticals Industries Ltd, Petah Tikva, Israel) …
Understanding the Impact of Urinary Incontinence in Persons with Dementia: Development of an Interdisciplinary Service Model.
Juliebø-Jones P, Coulthard E, Mallam E, Archer H, Drake MJ. Juliebø-Jones P, et al. Adv Urol. 2021 Jun 19;2021:9988056. doi: 10.1155/2021/9988056. eCollection 2021. Adv Urol. 2021. PMID: 34239557 Free PMC article.
Average score for how much urine leakage interferes with everyday life was 7.7/10 (range 2-10). 58.7% (n = 44) revealed some degree of sleep disturbance due to UI. 83% (n = 62) stated daily activities were limited due to UI. Two-thirds of persons with dementia (n = 50) sta …
Average score for how much urine leakage interferes with everyday life was 7.7/10 (range 2-10). 58.7% (n = 44) revealed some degree of sleep …
26 results